Relypsa (RLYP) stock had a bullish inflow of $2.12 million worth of trades on uptick and an outflow of $1.59 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.33. The net money flow into the stock was $0.53 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.1 million. $0.1 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Relypsa (RLYP) stock traded down $0.08 , and reached $19.91, a drop of -0.4% over the previous day. On a weekly basis, the stock is -1.29%, over the previous weeks close.
The stock has recorded a 20-day Moving Average of 8.09% and the 50-Day Moving Average is 14.62%. Shares have dropped -37.52% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $35.97 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $18.43 and the 200 Day Moving Average price is recorded at $17.72.
Relypsa (NASDAQ:RLYP): The stock opened at $20.18 on Thursday but the bulls could not build on the opening and the stock topped out at $20.30 for the day. The stock traded down to $19.70 during the day, due to lack of any buying support eventually closed down at $19.93 with a loss of -0.30% for the day. The stock had closed at $19.99 on the previous day. The total traded volume was 972,780 shares.
In an insider trading activity, The director, of Relypsa Inc, Torley Helen had unloaded 1,013 shares at $19.32 per share in a transaction on June 7, 2016. The total value of transaction was $19,571. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.